By Professor Jason Grebely

Journal articles

Nolan S; Dias Lima V; Fairbairn N; Kerr T; Montaner J; Grebely J; Wood E, 2014, 'The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users', Addiction, 109, pp. 2053 - 2059, http://dx.doi.org/10.1111/add.12682

Hajarizadeh B; Grady B; Page K; Kim AY; McGovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M; Amin J; Schinkel J; Applegate T; Maher L; Hellard M; Lloyd AR; Prins M; Geskus RB; Dore GJ; Grebely J; Lauer G; Shoukry NH; Hahn J; Shiboski S; Rice TM; Alavi M; Bouchard R; Aneja J; Teutsch S; White B; Wells B; Zang G; Matthews G; Marks P; Yeung B; Prince LE; Roy E; Bates A; Enriquez J; Chow S; McCredie L; Aitken C; Doyle J; Spelman T; Evans J, 2014, 'Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: The InC3 Study', Journal of Clinical Virology, 61, pp. 430 - 434, http://dx.doi.org/10.1016/j.jcv.2014.08.027

Jacka B; Applegate T; Krajden M; Olmstead A; Harrigan PR; Marshall BDL; Debeck K; Milloy MJ; Lamoury F; Pybus OG; Lima VD; Magiorkinis G; Montoya V; Montaner J; Joy J; Woods C; Dobrer S; Dore GJ; Poon AFY; Grebely J, 2014, 'Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, Canada', Hepatology, 60, pp. 1571 - 1580, http://dx.doi.org/10.1002/hep.27310

Hajarizadeh B; Grebely J; Applegate T; Matthews GV; Amin J; Petoumenos K; Hellard M; Rawlinson W; Lloyd A; Kaldor J; Dore GJ; Dolan K, 2014, 'Dynamics of HCV RNA Levels During Acute Hepatitis C Virus Infection', Journal of Medical Virology, 86, pp. 1722 - 1729, http://dx.doi.org/10.1002/jmv.24010

MacParland SA; Bilodeau M; Grebely J; Bruneau J; Cooper C; Klein M; Sagan SM; Choucha N; Balfour L; Bialystok F; Krajden M; Raven J; Roberts E; Russell R; Houghton M; Tyrrell DL; Feld JJ; Butt G; Conway B; Edwards A; Fischer B; Götte M; Kneteman N; Krahn M; Levy G; Liu Q; McGilvray I; Michalak T; Mugford G; Myers R; Ostrowski M; Pause A; Pezacki J; Richardson C; Schang L; Shoukry N; Sonenberg N; Soudeyns H; Tellier R; Tyndall M; Wilson J; Boisvert M; Depla M; Dupont B; Ehteshami M; Issur M; Olmstead A; Sarhan M; Siu R; Van Buuren N; Ablenas C; Bernier A; Cunningham E; Fabre T; Fahmy A; Hoffman B; Hyrina A; Kofahi H; Kulkarni A; Moqueet N; Ardakan NN; Singaravelu R; Thibault P; Wu Q; Artenie A; Puzhko S; Saeed S; Taylor N; Wong J; Cumming A, 2014, 'The 3rd Canadian symposium on Hepatitis c Virus: Expanding care in the interferon-free era', Canadian Journal of Gastroenterology and Hepatology, 28, pp. 481 - 487, http://dx.doi.org/10.1155/2014/704919

Grebely J; Lima VD; Marshall BDL; Milloy MJ; DeBeck K; Montaner J; Simo A; Krajden M; Dore GJ; Kerr T; Wood E, 2014, 'Declining incidence of hepatitis C virus infection among people who inject drugs in a Canadian setting, 1996-2012', Plos One, 9, pp. e97726, http://dx.doi.org/10.1371/journal.pone.0097726

Iversen J; Grebely J; Topp L; Wand H; Dore G; Maher L, 2014, 'Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011', Journal of Viral Hepatitis, 21, pp. 198 - 207, http://dx.doi.org/10.1111/jvh.12129

Treloar C; Rance J; Dore GJ; Grebely J, 2014, 'Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: Insights from the ETHOS study', Journal of Viral Hepatitis, 21, pp. 560 - 567, http://dx.doi.org/10.1111/jvh.12183

Grebely J; Dore GJ, 2014, 'Can hepatitis C virus infection be eradicated in people who inject drugs?', Antiviral Research, 104, pp. 62 - 72, http://dx.doi.org/10.1016/j.antiviral.2014.01.002

Alavi M; Raffa JD; Deans GD; Lai C; Krajden M; Dore GJ; Tyndall MW; Grebely J, 2014, 'Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents', Liver International, 34, pp. 1198 - 1206, http://dx.doi.org/10.1111/liv.12370

Baker D; Alavi M; Erratt A; Hill S; Balcomb A; Hallinan R; Siriragavan S; Richmond D; Smart J; Keats J; Doong N; Marks P; Grebely J; Dore GJ, 2014, 'Delivery of treatment for hepatitis C virus infection in the primary care setting', European Journal of Gastroenterology and Hepatology, 26, pp. 1003 - 1009, http://dx.doi.org/10.1097/MEG.0000000000000150

Baker D; Alavi M; Erratt A; Hill S; Balcomb A; Hallinan R; Siriragavan S; Richmond D; Smart J; Keats J; Doong N; Marks P; Grebely J; Dore GJ, 2014, 'Delivery of treatment for hepatitis C virus infection in the primary care setting', Journal of Nursing Administration, 44, pp. 1003 - 1009, http://dx.doi.org/10.1097/MEG.0000000000000150

Grebely J; Grady B; Hajarizadeh B; Page K; Dore GJ, 2014, 'Disease progression during advanced fibrosis: IL28B genotype or HCV RNA levels?', Hepatology, 59, pp. 1650 - 1651, http://dx.doi.org/10.1002/hep.26675

Aspinall EJ; Weir A; Sacks-Davis R; Spelman T; Grebely J; Higgs P; Hutchinson SJ; Hellard ME, 2014, 'Does informing people who inject drugs of their hepatitis C status influence their injecting behaviour? Analysis of the networks ii study', International Journal of Drug Policy, 25, pp. 179 - 182, http://dx.doi.org/10.1016/j.drugpo.2013.08.005

Alavi M; Law MG; Grebely J; Thein HH; Walter S; Amin J; Dore GJ; Han A, 2014, 'Lower life expectancy among people with an HCV notification: A population-based linkage study', Journal of Viral Hepatitis, 21, pp. e10 - e18, http://dx.doi.org/10.1111/jvh.12245

Grebely J; Page K; Sacks-Davis R; van der Loeff MS; Rice TM; Bruneau J; Morris MD; Hajarizadeh B; Amin J; Cox AL; Kim AY; Mcgovern BH; Schinkel J; George J; Shoukry NH; Lauer GM; Maher L; Lloyd AR; Hellard M; Dore GJ; Prins M, 2014, 'The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection', Hepatology, 59, pp. 109 - 120, http://dx.doi.org/10.1002/hep.26639

Treloar C; Rance J; Grebely J; Marks P; Dore G, 2014, 'How to build trustworthy hepatitis C services in an opioid treatment clinic? A qualitative study of clients and health workers in a co-located setting', International Journal of Drug Policy, 25, pp. 865 - 870, http://dx.doi.org/10.1016/j.drugpo.2014.01.011

Olmstead A; Krajden M; Montoya V; Grebely J; Poon AFY; Harrigan PR; Joy JB, 2014, 'MOLECULAR PHYLOGENETICS OF HEPATITIS C VIRUS (HCV) AS A TOOL TO UNDERSTAND THE HCV EPIDEMIC IN BRITISH COLUMBIA (BC), CANADA', JOURNAL OF HEPATOLOGY, 60, pp. S143 - S143, http://dx.doi.org/10.1016/S0168-8278(14)60394-9

Treloar C; Rance J; Grebely J; Dore GJ, 2013, 'Client and staff experiences of a co-located service for hepatitis C care in opioid substitution treatment settings in New South Wales, Australia', Drug and Alcohol Dependence, 133, pp. 529 - 534, http://dx.doi.org/10.1016/j.drugalcdep.2013.07.023

Feld JJ; Grebely J; Matthews GV; Applegate T; Hellard M; Sherker A; Cherepanov V; Petoumenos K; Yeung B; Kaldor JM; Lloyd AR; Dore GJ, 2013, 'Plasma interferon-gamma-inducible protein-10 levels are associated with early, but not sustained virological response during treatment of acute or early chronic HCV infection', Plos One, 8, pp. e80003, http://dx.doi.org/10.1371/journal.pone.0080003

Sacks-Davis R; Aitken CK; Higgs P; Spelman T; Pedrana AE; Bowden S; Bharadwaj M; Nivarthi UK; Suppiah V; George J; Grebely J; Drummer HE; Hellard M, 2013, 'High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: A prospective cohort study', Plos One, 8, http://dx.doi.org/10.1371/journal.pone.0080216

Martin NK; Vickerman P; Grebely J; Hellard M; Hutchinson SJ; Lima VD; Foster GR; Dillon JF; Goldberg DJ; Dore GJ; Hickman M, 2013, 'Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals', Hepatology, 58, pp. 1598 - 1609, http://dx.doi.org/10.1002/hep.26431

Grebely J; Matthews GV; Lloyd AR; Dore GJ, 2013, 'Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: Feasibility and future requirements', Clinical Infectious Diseases, 57, pp. 1014 - 1020, http://dx.doi.org/10.1093/cid/cit377

Hajarizadeh B; Grebely J; Dore GJ, 2013, 'Epidemiology and natural history of HCV infection', Nature Reviews Gastroenterology and Hepatology, 10, pp. 553 - 562, http://dx.doi.org/10.1038/nrgastro.2013.107

Alavi M; Grebely J; Micallef M; Dunlop AJ; Balcomb AC; Day CA; Treloar C; Bath N; Haber PS; Dore GJ, 2013, 'Assessment and treatment of hepatitis c virus infection among people who inject drugs in the opioid substitution setting: ETHOS study', Clinical Infectious Diseases, 57, pp. S62 - S69, http://dx.doi.org/10.1093/cid/cit305

Hilsden RJ; Macphail G; Grebely J; Conway B; Lee SS, 2013, 'Directly observed pegylated interferon plus self-administered ribavirin for the treatment of hepatitis C virus infection in people actively using drugs: A randomized controlled trial', Clinical Infectious Diseases, 57, pp. S90 - S96, http://dx.doi.org/10.1093/cid/cit327

Robaeys G; Grebely J; Mauss S; Bruggmann P; Moussalli J; De Gottardi A; Swan T; Arain A; Kautz A; Stöver H; Wedemeyer H; Schaefer M; Taylor L; Backmund M; Dalgard O; Prins M; Dore GJ, 2013, 'Recommendations for the management of hepatitis C virus infection among people who inject drugs', Clinical Infectious Diseases, 57, pp. S129 - S137, http://dx.doi.org/10.1093/cid/cit302

Aspinall EJ; Corson S; Doyle JS; Grebely J; Hutchinson SJ; Dore GJ; Goldberg DJ; Hellard ME, 2013, 'Treatment of hepatitis c virus infection among people who are actively injecting drugs: A systematic review and meta-analysis', Clinical Infectious Diseases, 57, pp. S80 - S89, http://dx.doi.org/10.1093/cid/cit306

Jacka B; Lamoury F; Simmonds P; Dore GJ; Grebely J; Applegate T, 2013, 'Sequencing of the Hepatitis C Virus: A Systematic Review', Plos One, 8, pp. e67073, http://dx.doi.org/10.1371/journal.pone.0067073

Grebely J; Feld JJ; Applegate T; Matthews GV; Hellard M; Sherker A; Petoumenos K; Zang G; Shaw I; Yeung B; George J; Teutsch S; Kaldor JM; Cherepanov V; Bruneau J; Shoukry NH; Lloyd AR; Dore GJ, 2013, 'Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection', Hepatology, 57, pp. 2124 - 2134, http://dx.doi.org/10.1002/hep.26263

Deans GD; Raffa JD; Lai C; Fischer B; Krajden M; Amin J; Walter SR; Dore GJ; Grebely J; Tyndall MW, 2013, 'Mortality in a large community-based cohort of inner-city residents in Vancouver, Canada', CMAJ Open, 1, pp. e68 - e76, http://dx.doi.org/10.9778/cmajo.20130002

Grebely J; Bilodeau M; Feld JJ; Bruneau J; Fischer B; Raven JF; Roberts E; Choucha N; Myers RP; Sagan SM; Wilson JA; Bialystok F; Lorne Tyrrell D; Houghton M; Krajden M, 2013, 'The Second Canadian Symposium on Hepatitis C Virus: A call to action', Canadian Journal of Gastroenterology, 27, pp. 627 - 632, http://dx.doi.org/10.1155/2013/242405

Grebely J; Oser ML; Taylor L; Dore GJ, 2013, 'Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: Action required at the system, provider, and patient levels', Journal of Infectious Diseases, 207, pp. S19 - S25, http://dx.doi.org/10.1093/infdis/jis928

Suppiah V; Armstrong NJ; O'Connor KS; Berg T; Weltman M; Abate ML; Spengler U; Bassendine M; Dore GJ; Irving WL; Powell E; Nattermann J; Mueller T; Riordan S; Stewart GJ; George J; Booth DR; Ahlenstiel G; Michalk M; Malik B; McClure P; Smith S; Sheridan D; Snape E; Fragomeli V; Norris R; How-Chow D; Jonsson JR; Barrie H; Stelzer-Braid S; Fletcher S; Applegate T; Grebely J; Matthews G; Bharadwaj M; Smedile A, 2013, 'CCR5-Δ32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection', Genes and Immunity, 14, pp. 286 - 290, http://dx.doi.org/10.1038/gene.2013.15

Post J; Arain A; Lloyd AR; Grebely J; Dore G, 2013, 'Enhancing Assessment and Treatment Hepatitis C in the Custodial Setting', Clinical Infectious Diseases, 57, pp. S70 - S74, http://dx.doi.org/10.1093/cid/cit264

Hellard M; Grebely J; Yeung B; Dore G; Marks P; Shaw D; Byrne M; Matthews G, 2012, 'EFFECTIVENESS OF RESPONSE-GUIDED THERAPY IN RECENT HEPATITIS C INFECTION: THE AUSTRALIAN TRIAL IN ACUTE HEPATITIS C', DRUG AND ALCOHOL REVIEW, 31, pp. 33 - 33

Grebely J; Alavi M; Spelman T; Haber P; Day C; Matthews G; Van Beek I; Walsh N; Yeung B; Petoumenos K; Dolan K; Kaldor J; Dore G; Hellard M, 2012, 'IMPACT OF TREATMENT OF RECENTLY-ACQUIRED HEPATITIS C INFECTION ON INJECTING DRUG USE BEHAVIOURS', DRUG AND ALCOHOL REVIEW, 31, pp. 34 - 34

Hajarizadeh B; Grebely J, 2012, 'HIV and Liver Disease', PRACTICAL GASTROENTEROLOGY, 36, pp. 46 - 46, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000421778800005&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Sacks-davis R; Horyniak D; Grebely J; Hellard M, 2012, 'Behavioural interventions for preventing hepatitis C infection in people who inject drugs: A global systematic review', International Journal of Drug Policy, 23, pp. 176 - 184, http://dx.doi.org/10.1016/j.drugpo.2011.08.002

Hajarizadeh B; Grebely J; Dore GJ, 2012, 'Case definitions for acute hepatitis C virus infection: A systematic review', Journal of Hepatology, 57, pp. 1349 - 1360, http://dx.doi.org/10.1016/j.jhep.2012.07.007

Grebely J; Morris M; Rice T; Bruneau J; Cox AL; Kim A; McGovern B; Shoukry N; Lauer G; Maher L; Lloyd AR; Hellard M; Prins M; Dore GJ; Page K, 2012, 'Cohort Profile: The International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3) Study.', International Journal of Epidemiology, in press, pp. 1-11, http://dx.doi.org/10.1093/ije/dys167

Grebely J; Matthews GV; Petoumenos K; Yeung B; Day C; Lloyd AR; Beek IV; Kaldor JM; Hellard M; Dore GJ; Haber PS; Alavi M; Van Beek I; Amin J; Dolan K; Rawlinson W; Flynn J; Marks P; Acraman B; Bloch M; Li H; Madden A; George J, 2012, 'Effect of pegylated interferon-a-2a treatment on mental health during recent hepatitis C virus infection', Journal of Gastroenterology and Hepatology, 27, pp. 957 - 965, http://dx.doi.org/10.1111/j.1440-1746.2011.07035.x

Grebely J; Prins M; Hellard M; Cox AL; Osburn WO; Lauer G; Page K; Lloyd AR; Dore GJ; Maher L, 2012, 'Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine', Lancet Infectious Diseases, 12, pp. 408 - 414, http://dx.doi.org/10.1016/S1473-3099(12)70010-5

Sacks-davis R; Daraganova G; Aitken CK; Higgs P; Tracy L; Bowden S; Jenkinson R; Rolls D; Pattison P; Robins G; Grebely J; Barry A; Hellard M, 2012, 'Hepatitis C Virus Phylogenetic Clustering Is Associated with the Social-Injecting Network in a Cohort of People Who Inject Drugs', PLoS ONE, 7, pp. Article number e47335, http://dx.doi.org/10.1371/journal.pone.0047335

Grebely J; Pham ST; Matthews G; Petoumenos K; Bull RA; Yeung B; Rawlinson WD; Kaldor JM; Lloyd AR; Hellard M; Dore GJ; White PA; Bull ; Dolan K, 2012, 'Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection', Hepatology, 55, pp. 1058 - 1069, http://dx.doi.org/10.1002/hep.24754

Treloar C; Hull PB; Dore GJ; Grebely J, 2012, 'Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs', Drug and Alcohol Review, 31, pp. 918 - 924, http://dx.doi.org/10.1111/j.1465-3362.2012.00468.x

Grebely J; Talwalkar J, 2012, 'Recognizing and preventing death from compensated cirrhosis in the community.', Liver International, 32, pp. 2 - 4, http://dx.doi.org/10.1111/j.1478-3231.2011.02627.x

Vickerman P; Grebely J; Dore GJ; Sacks-davis R; Page K; Thomas DL; Osburn WO; Cox AL; Aitken CL; Hickman M; Hellard M; Maher L, 2012, 'The more you look, the more you find: Effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design', Journal of Infectious Diseases, 205, pp. 1342 - 1350, http://dx.doi.org/10.1093/infdis/jis213

Grebely J; Hellard M; Applegate TL; Petoumenos K; Yeung B; Feld J; Rawlinson WD; Lloyd AR; George J; Kaldor JM; Dore GJ; Matthews G; Dolan K, 2012, 'Virological responses during treatment for recent hepatitis C virus: Potential benefit for ribavirin use in HCV/HIV co-infection', AIDS, 26, pp. 1653 - 1661, http://dx.doi.org/10.1097/QAD.0b013e3283553719

Grebely J; Dore GJ, 2012, 'What is killing people with hepatitis C virus infection?', Seminars in Liver Disease, 31, pp. 331 - 339, http://dx.doi.org/10.1055/s-0031-1297922

Back to profile page